These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33369999)

  • 1. Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction: Challenging Cases and Practical Algorithms.
    Bahabri A; Chan AKC; Belostosky V; Bhatt MD
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1040-e1044. PubMed ID: 33369999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
    May CC; Cua S; Smetana KS; Powers CJ
    World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
    Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
    Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual Enoxaparin Activity, Anti-Xa Levels, and Concerns About the American Society of Regional Anesthesia and Pain Medicine Anticoagulation Guidelines.
    Henshaw DS; Turner JD; Forest DJ; Thompson GR; Weller RS
    Reg Anesth Pain Med; 2017; 42(4):432-436. PubMed ID: 28492441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of anti-factor Xa monitoring in a selection of patients receiving enoxaparin at a large academic medical center.
    Sacha GL; Greenlee KM; Ketz JM
    J Thromb Thrombolysis; 2016 Nov; 42(4):479-85. PubMed ID: 27256341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis.
    Pannucci CJ; Hunt MM; Fleming KI; Prazak AM
    Plast Reconstr Surg; 2017 Oct; 140(4):815-822. PubMed ID: 28953735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients.
    Bigos R; Solomon E; Dorfman JD; Ha M
    J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding.
    Pannucci CJ; Fleming KI; Momeni A; Prazak AM; Agarwal J; Rockwell WB
    Plast Reconstr Surg; 2018 Jun; 141(6):1580-1590. PubMed ID: 29608533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.
    Aleidan FAS; Aljarba GA; Aldakhil AA; Allehyani BI; Yahia MA; Alghtani NE; Badri M; Alaklabi AA; Alsuhaibani A; Crowther MA
    Int J Hematol; 2020 Jul; 112(1):1-7. PubMed ID: 32266670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of an Extended Interval Fondaparinux Dosing Regimen for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Severe Renal Dysfunction Using Antifactor Xa Levels.
    Wahby KA; Riley LK; Tennenberg SD
    Pharmacotherapy; 2017 Oct; 37(10):1241-1248. PubMed ID: 28833353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
    Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
    JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enoxaparin dosing after cesarean delivery in morbidly obese women.
    Overcash RT; Somers AT; LaCoursiere DY
    Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
    Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB
    JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight-Based Enoxaparin Achieves Adequate Anti-Xa Levels More Often in Trauma Patients: A Prospective Study.
    Stutsrim AE; Eady JM; Collum M; Rebo GJ; Rebo KA; Miller PR; Nunn AM
    Am Surg; 2021 Jan; 87(1):77-82. PubMed ID: 32915054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.